Effects of Pimozide Derivatives on pSTAT5 in K562 Cells

STAT5 is a transcription factor, a member of the STAT family of signaling proteins. STAT5 is involved in many types of cancer, including chronic myelogenous leukemia (CML), in which this protein is found constitutively activated as a consequence of BCR‐ABL expression. The neuroleptic drug pimozide was recently reported to act as an inhibitor of STAT5 phosphorylation and is capable of inducing apoptosis in CML cells in vitro. Our research group has synthesized simple derivatives of pimozide with cytotoxic activity and that are able to decrease the levels of phosphorylated STAT5. In this work we continued the search for novel STAT5 inhibitors, synthesizing compounds in which the benzoimidazolinone ring of pimozide is either maintained or modified, in order to obtain further structure–activity relationship information for this class of STAT5 inhibitors. Two compounds of the series showed potent cytotoxic activity against BCR‐ABL‐positive and pSTAT5‐overexpressing K562 cells and were able to markedly decrease the levels of phosphorylated STAT5.

[1]  Y. Saunthararajah,et al.  Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia , 2012, European journal of haematology.

[2]  A. Ganser,et al.  BCR-ABL Affects STAT5A and STAT5B Differentially , 2014, PloS one.

[3]  J. Griffin,et al.  The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. , 2012, Genes & cancer.

[4]  A. Mui,et al.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells , 1999, The EMBO journal.

[5]  D. Frank,et al.  Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells , 2012, Leukemia.

[6]  J. Darnell,et al.  SnapShot: JAK-STAT Signaling , 2007, Cell.

[7]  Sean Ekins,et al.  Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis , 2006, Pharmaceutical Research.

[8]  F. Dieli,et al.  The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR–ABL-expressing leukemia cells , 2013, Anti-cancer drugs.

[9]  T. Berg,et al.  Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. , 2015, ACS chemical biology.

[10]  B. Ebert,et al.  The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. , 2011, Blood.

[11]  R. Ilaria,et al.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice. , 2006, Blood.

[12]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.

[13]  R. Baruchello,et al.  Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. , 2014, Bioorganic & medicinal chemistry letters.

[14]  David E. Muench,et al.  Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein , 2014, ACS medicinal chemistry letters.

[15]  T. Berg,et al.  Nanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a , 2015, Angewandte Chemie.

[16]  L. Hennighausen,et al.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia , 2010, EMBO molecular medicine.

[17]  V. Sexl,et al.  JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. , 2013, Blood.

[18]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[19]  Marja T Nevalainen,et al.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers. , 2008, Endocrine-related cancer.